190430-36-5

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazolo[3,4-d]pyrimidine, 3-bromo-4-methoxyis used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure, including the bromine and methoxy groups, may contribute to the development of new drugs with specific therapeutic properties.
Used in Chemical Research:
1H-Pyrazolo[3,4-d]pyrimidine, 3-bromo-4-methoxyis used as a research tool in chemical laboratories to study the properties and reactions of pyrazolo[3,4-d]pyrimidine derivatives. Understanding its reactivity and behavior in different chemical environments can help in designing new synthetic routes and applications.
Used in Biological Studies:
1H-Pyrazolo[3,4-d]pyrimidine, 3-bromo-4-methoxymay be utilized in biological research to investigate its interactions with biological molecules, such as proteins and nucleic acids. This can provide insights into its potential use as a bioactive molecule or its role in biological processes.

Upstream product

• 5399-92-8 4-chloro-1H-pyrazolo[3,4-d]pyrimidine 

Downstream Products

• 95087-07-3 2-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-4-methoxy-2H-pyrazolo[3,4-d]pyrimidine 
• 190430-39-8 3-bromo-2-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine 
• 190430-37-6 3-bromo-1-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine 
• 296800-37-8 3-bromo-2-[2-deoxy-5-O-(4,4'-dimethoxytriphenylmethyl)-β-D-erythro-pentafuranosyl]-4-[(dimethylamino)ethylidene]-2H-pyrazolo[3,4-d]pyrimidin-4-amine 

Relevant academic research and scientific papers

Revisiting Pyrazolo[3,4- d]pyrimidine Nucleosides as Anti- Trypanosoma cruzi and Antileishmanial Agents

Chagas disease and visceral leishmaniasis are two neglected tropical diseases responsible for numerous deaths around the world. For both, current treatments are largely inadequate, resulting in a continued need for new drug discovery. As both kinetoplastid parasites are incapable of de novo purine synthesis, they depend on purine salvage pathways that allow them to acquire and process purines from the host to meet their demands. Purine nucleoside analogues therefore constitute a logical source of potential antiparasitic agents. Earlier optimization efforts of the natural product tubercidin (7-deazaadenosine) involving modifications to the nucleobase 7-position and the ribofuranose 3′-position led to analogues with potent anti-Trypanosoma brucei and anti-Trypanosoma cruzi activities. In this work, we report the design and synthesis of pyrazolo[3,4-d]pyrimidine nucleosides with 3′- and 7-modifications and assess their potential as anti-Trypanosoma cruzi and antileishmanial agents. One compound was selected for in vivo evaluation in an acute Chagas disease mouse model.